|
1
|
Reiter RE, Gu Z, Watabe T, et al: Prostate
stem cell antigen: A cell surface maker overexpressed in prostate
cancer. Proc Natl Acad Sci USA. 95:1735–1740. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gu Z, Thomas G, Yamashiro J, et al:
Prostate stem cell antigen (PSCA) expression increases with high
gleason score, advanced stage and bone metastasis in prostate
cancer. Oncogene. 19:1288–1296. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Krupa M, Canamero M, Gomez CE, Najera JL,
Gil J and Esteban M: Immunization with recombinant DNA and modified
vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1
antigens inhibits prostate cancer progression. Vaccine.
29:1504–1513. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garcia-Hernandez Mde L, Gray A, Hubby B,
Klinger OJ and Kast WM: Prostate stem cell antigen vaccination
induces a long-term protective immune response against prostate
cancer in the absence of autoimmunity. Cancer Res. 68:861–869.
2008.PubMed/NCBI
|
|
5
|
Ahmad S, Casey G, Cronin M, Rajendran S,
Sweeney P, Tangney M and O’Sullivan GC: Induction of effective
antitumor response after mucosal bacterial vector mediated DNA
vaccination with endogenous prostate cancer specific antigen. J
Urol. 186:687–693. 2011. View Article : Google Scholar
|
|
6
|
Srivastava PK and Udono H: Heat shock
protein-peptide complexes in cancer immunotherapy. Curr Opin
Immunol. 6:728–732. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Srivastava PK, Udono H, Blachere NE and Li
Z: Heat shock proteins transfer peptides during antigen processing
and CTL priming. Immunogenetics. 39:93–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blachere NE and Srivastava PK: Heat shock
protein-based cancer vaccines and related thoughts on
immunogenicity of human tumors. Semin Cancer Biol. 6:349–355. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matsueda S, Kobayashi K, Nonaka Y, Noguchi
M, Itoh K and Harada M: Identification of new prostate stem cell
antigen-derived peptides immunogenic in HLA-A2(+) patients with
hormone-refractory prostate cancer. Cancer Immunol Immunother.
53:479–489. 2004.PubMed/NCBI
|
|
10
|
Bahrenberg G, Brauers A, Joost HG and
Jakse G: PSCA expression is regulated by phorbol ester and cell
adhesion in the bladder carcinoma cell line RT112. Cancer Lett.
168:37–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Argani P, Rosty C, Reiter RE, et al:
Discovery of new markers of cancer through serial analysis of gene
expression: prostate stem cell antigen is overexpressed in
pancreatic adenocarcinoma. Cancer Res. 61:4320–4324.
2001.PubMed/NCBI
|
|
12
|
Dannull J, Diener PA, Prikler L, et al:
Prostate stem cell antigen is a promising candidate for
immunotherapy of advanced prostate cancer. Cancer Res.
60:5522–5528. 2000.PubMed/NCBI
|
|
13
|
Saffran DC, Raitano AB, Hubert RS, Witte
ON, Reiter RE and Jakobovits A: Anti-PSCA mAbs inhibit tumor growth
and metastasis formation and prolong the survival of mice bearing
human prostate cancer xenografts. Proc Natl Acad Sci USA.
98:2658–2663. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blachere NE, Li Z, Chandawarkar RY, et al:
Heat shock protein-peptide complexes, reconstituted in vitro,
elicit peptide-specific cytotoxic T lymphocyte response and tumor
immunity. J Exp Med. 186:1315–1322. 1997. View Article : Google Scholar
|
|
15
|
Srivastava PK: Immunotherapy for human
cancer using heat shock protein-peptide complexes. Curr Oncol Rep.
7:104–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI
and Mizzen LA: Immunotherapy of a human papillomavirus (HPV) type
16 E7-expressing tumour by administration of fusion protein
comprising Mycobacterium bovis bacille Calmette-Guérin (BCG)
hsp65 and HPV16 E7. Clin Exp Immunol. 121:216–225. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu
HK, Xiao X and Chen SL: Recombinant adeno-asseciated virus
expressing human papilomavirus type 16 E7 peptide DNA fused with
heat shock protein DNA as a potential vaccine for cervical cancer.
J Virol. 74:2888–2894. 2000. View Article : Google Scholar
|
|
18
|
Zhang X, Yu C, Zhao J, et al: Vaccination
with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances
the antigen-specific CD8+ T-cell response and inhibits
the PSCA+ tumors growth in mice. J Gene Med. 9:715–726.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu X, Zhao X, Burkholder WF, Gragerov A,
Ogata CM, Gottesman ME and Hendrickson WA: Structural analysis of
substrate binding by the molecular chaperone DnaK. Science.
272:1606–1614. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Kelly CG, Singh M, McGowan EG,
Carrara AS, Bergmeier LA and Lehner T: Stimulation of
TH1-polarizing cytokines, C-C chemokines, maturation of dendritic
cells and adjuvant function by the peptide binding fragment of heat
shock protein 70. J Immunol. 169:2422–2429. 2002. View Article : Google Scholar
|
